Bispecific Drugs for Cancers
Exhibitor: CENTER FOR BIOMEDICAL RESEARCH AND DEVELOPMENT, NCKU
Booth No: N516
Characteristic
The existing drugs for glioblastoma and pancreatic cancer cannot effectively improve the overall survival rate of patients. We have successfully developed bispecific drugs targeting integrins and VEGFR2 pathways that can significantly reduce tumor growth and increase the survival rate. Our animal analyses showed that they are effective protein drugs for the treatments of glioblastoma and pancreatic cancer.
Other Products
Highest Rated Products